
Novo Nordisk has met its primary endpoint in two phase III studies of once-weekly insulin icodec, the Danish pharmaceutical company has announced in a press release.
The two studies, Onwards 3 and Onwards 4, are a part of the Onwards program, which is comprised of 6 studies. With three sub-programs having already reported promising results, there is now only one left, expected to conclude during the second half of 2022.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app